 |
|
|
| |
Week 48 results of AMBER: A Phase 3, randomised, double-blind trial in antiretroviral treatment-naïve HIV-1-infected adults to evaluate the
efficacy and safety of the once-daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) versus darunavir/cobicistat plus emtricitabine/tenofovir disoproxil fumarate
|
| |
| |
Reported by Jules Levin
16th European AIDS Conference, October 25-27, 2017. Milan
Joseph Eron1, Chloe Orkin2, Joel Gallant3, Jean-Michel Molina4, Eugenia Negredo5, Andrea Antinori6, Anthony Mills7, Jacques Reynes8, Erika Van Landuyt9, Erkki Lathouwers9, Veerle Hufkens9, John Jezorwski9, Magda Opsomer9, on behalf of the AMBER study group
1The University of North Carolina School of Medicine, Chapel Hill, NC; 2Barts Health NHS Trust, London, UK; 3Southwest CARE Center, Santa Fe, New Mexico, USA; 4Department of Infectious Diseases, St-Louis Hospital, University of Paris Diderot, Paris, France; 5Germans Trias i Pujol University Hospital, Badalona, Spain; 6National Institute for Infectious Diseases, L. Spallanzani IRCCS, Rome, Italy; 7Southern California Men's Medical Group, Los Angeles, CA, USA; 8Montpellier University Hospital, Montpellier, France; 9Janssen Pharmaceutica NV, Beerse, Belgium
|
| |
|
|
|
|
|
